Recombinant Varicella Zoster Virus gE (VZV gE) antibody

Catalog No. ABIN7482309

The Human Monoclonal anti-Varicella Zoster Virus gE antibody (Clone 1B10) (ABIN7482309) specifically detects Varicella Zoster Virus gE in ELISA. The antibody is reactive with Varicella Zoster Virus (VZV) samples.

Quick Overview for Recombinant Varicella Zoster Virus gE (VZV gE) antibody (ABIN7482309)

Target: Varicella Zoster Virus gE (VZV gE)

Antibody Type: Recombinant Antibody

Reactivity: Varicella Zoster Virus (VZV)

Host: Human

Clonality: Monoclonal

Conjugate: Un-conjugated

Application: ELISA

Grade: MALS verified

Clone: 1B10

Product Details

Purpose: Anti-Glycoprotein E (VZV) Antibody, Human IgG1 (1B10) (MALS verified)

Isotype: IgG1

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Storage: -20 °C

Target Details

Target: Varicella Zoster Virus gE (VZV gE)

Alternative Name: VZV gE

Target Type: Viral Protein

Background: Varicella-zoster virus (VZV) is a neurotropic virus belonging to the Herpesviridae family. Primary VZV infection causes chickenpox and is followed by a life-long latent infection established mainly in the cranial and dorsal root ganglia. Reactivation of the virus is often associated with shingles (herpes zoster). Glycoprotein E (gE) is one of the known glycoproteins (gB, gC, gE, gH, gI, gK, gI) of VZV that is most abundantly expressed on the surface of virus and infected cells, playing an important role in viral replication and cell-to-cell spread. The strongly immunogenic gE can provide strong IgG signal in body fluid, which makes it ideal to be developed as an antigen for analysis of IgG antibodies. gE also demonstrates high potency as a vaccine immunogen and is formulated as the single viral envelope protein that constitutes the GSK VZV recombinant subunit vaccine Shingrix®.The antibody can reacte with gE specially.